AEON Biopharma: Navigating the CEO Transition

In the fast-paced world of biopharmaceuticals, leadership transitions can be as impactful as a new drug approval. AEON Biopharma, a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for multiple therapeutic indications, announced on March 27, 2025, that Marc Forth is stepping down as President and CEO to pursue another opportunity. Effective April 4, 2025, Jost Fischer, the current Chairman of the Board, will assume the role of interim CEO while the Board identifies a permanent replacement. This transition comes at a critical juncture for AEON, as the company navigates the 351(k) biosimilar regulatory pathway for its ABP-450 product, aiming to bring it to the U.S. market for all of BOTOX’s currently approved and future therapeutic indications under a single FDA approval.



The stakes are high for AEON. The company's progress along the 351(k) biosimilar regulatory pathway is a pivotal moment that could determine its future success. ABP-450, the botulinum toxin complex developed by AEON, has the potential to revolutionize the treatment of multiple debilitating medical conditions. The upcoming Biosimilar BPD Type 2a meeting with the FDA, anticipated in the second half of 2025, is a crucial milestone that could either propel AEON to new heights or leave it struggling to regain its footing.

Fischer's appointment as interim CEO brings a mix of stability and uncertainty. On one hand, Fischer's extensive experience in leadership roles, including his tenure as CEO of Sirona and The Hoermann Group, suggests that he has the managerial skills necessary to navigate the company through this transitional period. His familiarity with AEON, having served on the Board since February 2017, provides institutional knowledge and a deep understanding of the company's strategic direction. This continuity is essential as AEON prepares for its regulatory meeting with the FDA.

However, Fischer's limited background in biopharmaceuticals could pose a risk. The biopharmaceutical industry is highly specialized and regulated, requiring a deep understanding of scientific research, clinical trials, and regulatory processes. Fischer's experience in the telecommunication, automotive, and paper industries may not directly translate to the complexities of developing and commercializing biopharmaceutical products. This lack of industry-specific expertise could potentially hinder AEON's progress in its 351(k) biosimilar regulatory pathway for ABP-450.

Despite these risks, Fischer's appointment also presents opportunities. His experience in leading international conglomerates and his role as co-owner of Dental Innovations BVBA demonstrate his ability to manage complex organizations and drive strategic growth. Additionally, Fischer's appointment as interim CEO allows the Board to actively consider several qualified candidates for the permanent role, ensuring that the company can find a leader with the right blend of industry expertise and managerial skills.



The appointment of Fischer as interim CEO is a strategic move by AEON's Board to ensure operational continuity during this critical period. Fischer's commitment to maintaining AEON's momentum and ensuring that the company's development program for ABP-450 remains on track is evident in his statement: "I look forward to working with the AEON team and the Board to ensure our program for ABP-450 continues to move forward without delay. We believe our current cash balance will allow us to work through our Biosimilar BPD Type 2a meeting with FDA anticipated in the second half of 2025."

In conclusion, the leadership transition at AEON Biopharma introduces both risks and opportunities. While Fischer's appointment as interim CEO provides stability and continuity, his limited background in biopharmaceuticals poses potential challenges. However, the company's proactive measures, including Fischer's interim leadership and Forth's continued advisory role, aim to mitigate these risks. As AEON navigates the upcoming regulatory milestones, investors and stakeholders will be closely watching the company's strategic direction and operational continuity. The success of ABP-450 and AEON's ability to bring it to market could have a significant impact on the biopharmaceutical industry and the lives of patients suffering from debilitating medical conditions.